Dronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter and other cardiovascular risk factors, reflecting the parameters of its effectiveness in clinical trials. © 2011 The Cleveland Clinic Foundation.
CITATION STYLE
Penugonda, N., Mohmand-Borkowski, A., & Burke, J. F. (2011). Dronedarone for atrial fibrillation: How does it compare with amiodarone? Cleveland Clinic Journal of Medicine, 78(3), 179–185. https://doi.org/10.3949/ccjm.78a.10049
Mendeley helps you to discover research relevant for your work.